Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/BIOGEN-INC-4853/news/BIOLOGICS-LICENSE-APPLICATION-FOR-LECANEMAB-DESIGNATED-FOR-PRIORITY-REVIEW-BY-CHINA-NATIONAL-MEDICAL-43103063/?utm_source=whatsapp&utm_medium=social&utm_campaign=share